OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Drug Metabolism & Toxicology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer	87
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity	74
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	55
High-throughput PBTK models for in vitro to in vivo extrapolation	49
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?	46
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	44
Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols?	44
The pharmacokinetics of antibiotics in cystic fibrosis	40
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	40
Alterations in drug disposition in older adults: a focus on geriatric syndromes	39
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	38
Drug metabolism in the lungs: opportunities for optimising inhaled medicines	35
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation	34
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems	33
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs	29
SULT genetic polymorphisms: physiological, pharmacological and clinical implications	27
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization	27
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	26
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder	26
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	25
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	25
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review	24
Genetic risk factors in the development of idiosyncratic drug-induced liver injury	22
Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease	20
GenotypingHLAalleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art	19

An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs)	19
A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients	18
Renal and non-renal response of ABC and SLC transporters in chronic kidney disease	17
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	17
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity	17
Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion	17
Genetic factors influencing the development of vincristine-induced neurotoxicity	16
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials	16
Drug-drug interactions between psychotropic medications and oral contraceptives	16
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	16
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	15
Novel test strategies for in vitro seizure liability assessment	15
Pharmacogenomics in Asians: Differences and similarities with other human populations	15
An update on drug–drug interactions associated with proton pump inhibitors	15
The role of cytochrome P450 (CYP) enzymes in hyperoxic lung injury	15
Coffee in cancer chemoprevention: an updated review	14
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	14
Circadian regulation of transporter expression and implications for drug disposition	14
Assessing the pharmacokinetics and toxicology of polymeric micelle conjugated therapeutics	14
The regulation of liver cytochrome P450 expression and activity by the brain serotonergic system in different experimental models	13
Xanthones as P-glycoprotein modulators and their impact on drug bioavailability	13
Evolving approaches on measurements and applications of intracellular free drug concentration and Kp_uu in drug discovery	13
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec	13
Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it	13
Evaluating the risk of manganese-induced neurotoxicity of parenteral nutrition: review of the current literature	13
An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables	12
Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs	12
Inositols in the ovaries: activities and potential therapeutic applications	12
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia	12
Novel models for the prediction of drug–gene interactions	12
Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism	12
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships	12
Xanthones from Securidaca inappendiculata antagonized the antirheumatic effects of methotrexate in vivo by promoting its secretion into urine.	12
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management	12
Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review	11
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature	11
Positioning the new drugs for migraine	11
Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy	11
Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs	11
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature	11
Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions	10
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	10
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	10
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice	10
Modeling drug transport within the viable skin - a review	10
A review on the clinical pharmacokinetics of hydralazine	9
Restoration and stabilization of acrylamide-induced DNA, mitochondrial damages and oxidative stress by chrysin in human lymphocyte	9
Exposure to antibiotics during pregnancy alters offspring outcomes	9
The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV	9
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions	9

Modeling drug-induced liver injury: current status and future prospects	9
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	9
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence	9
Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity	9
Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties	9
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more	9
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	9
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	8
CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia	8
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	8
AMPK activators for the prevention and treatment of neurodegenerative diseases	8
The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients	8
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	8
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	8
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies	8